Survey 23 - Antimicrobial Stewardship with Cefpodoxime ProxetilMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File Section 1: Prescription Practices & Awareness1. How often do you prescribe Cefpodoxime Proxetil 400 mg SR tablets in your practice? Very frequently (>10 patients/month) Occasionally (5-10 patients/month) Rarely (<5 patients/month) Never2. Which of the following conditions do you primarily prescribe Cefpodoxime Proxetil 400 mg SR for? (Select all that apply)Acute bacterial sinusitisCommunity-acquired pneumonia (CAP)Uncomplicated urinary tract infections (UTIs)Skin and soft tissue infections (SSTIs)Acute exacerbations of chronic bronchitis (AECB)Other (specify)Other (specify)3. What influences your decision to prescribe Cefpodoxime Proxetil 400 mg SR over immediate-release (IR) formulations? Better patient compliance (once-daily dosing) Sustained therapeutic levels for 24 hours Lower risk of resistance development Cost-effectiveness Other (specify)Others (specify)4. How do you perceive the bioavailability of Cefpodoxime Proxetil 400 mg SR compared to IR formulations? Significantly better Slightly better Comparable Not sureSection 2: Clinical Efficacy & Patient Outcomes5. In your experience, how effective is Cefpodoxime Proxetil 400 mg SR in achieving clinical cure rates in respiratory infections? Highly effective (>90% success) Moderately effective (70-90% success) Minimally effective (<70% success) Not sure6. How often do you observe treatment failure or resistance with Cefpodoxime Proxetil 400 mg SR? Rarely (<5% cases) Occasionally (5-15% cases) Frequently (>15% cases) No data7. Do you consider Cefpodoxime Proxetil 400 mg SR as a first-line empirical therapy for uncomplicated UTIs? Yes, frequently Only in specific cases No, prefer other antibiotics Not applicable8. How does the sustained-release mechanism impact patient adherence compared to conventional antibiotics? Significantly improves adherence Slightly improves adherence No difference Not sureSection 3: Safety & Tolerability9. What is your perception of the gastrointestinal (GI) tolerability of Cefpodoxime Proxetil 400 mg SR? Excellent (minimal side effects) Good (occasional mild GI disturbances) Moderate (frequent GI side effects) Poor (high discontinuation rates)10. Have you encountered any cases of Clostridioides difficile infection (CDI) associated with Cefpodoxime Proxetil use? Yes, rarely Yes, occasionally Never Not monitored11. How does the safety profile of Cefpodoxime Proxetil 400 mg SR compare to other oral cephalosporins? Better Similar Worse No opinionSection 4: Comparative Advantages & Cost Considerations12. In your opinion, what is the key advantage of Cefpodoxime Proxetil 400 mg SR over other oral antibiotics (e.g., Amoxicillin-Clavulanate, Levofloxacin)? Once-daily dosing Broader Gram-negative coverage Lower risk of resistance Better safety profile Other (specify)Other (specify)13. Do you consider Cefpodoxime Proxetil 400 mg SR cost-effective for Indian patients? Yes, highly cost-effective Moderately cost-effective Not cost-effective No opinion14. Would you prefer Cefpodoxime Proxetil 400 mg SR over multiple daily doses of IR formulations for working patients? Strongly agree Agree Neutral DisagreeSection 4: Comparative Advantages & Cost Considerations15. How concerned are you about emerging bacterial resistance to Cefpodoxime Proxetil in India? Very concerned Moderately concerned Slightly concerned Not concerned16. Do you follow antimicrobial stewardship guidelines while prescribing Cefpodoxime Proxetil 400 mg SR? Always Sometimes Rarely Not aware of guidelines17. What measures do you take to prevent resistance development when prescribing Cefpodoxime Proxetil? (Select all that apply)Culture sensitivity testing before prescribingShortest effective duration (5-7 days)Avoiding unnecessary prescriptionsPatient education on adherenceOther (specify)Others (specify)Section 6: Future Perspectives18. Would you recommend Cefpodoxime Proxetil 400 mg SR as a preferred choice for outpatient infections? Strongly recommend Recommend in select cases Neutral Would not recommend19. What additional data would help you prescribe Cefpodoxime Proxetil 400 mg SR more confidently? More real-world Indian studies Comparative trials vs. other cephalosporins Long-term resistance surveillance Cost-benefit analyses I have read and agree to the Terms and Conditions .Submit Form